Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
NCT06300489
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Rectal Cancer
Interventions
DRUG:
irinotecan liposomes+capecitabine
Sponsor
Zhejiang Cancer Hospital